SCHEMBL3341652

SCHEMBL3341652

CCOC(=O)c1cnc(-c2cccc(Cl)c2)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.55
JAK3 P52333 1/20 0.55
CYP1A2 P05177 4/20 0.54
CYP2C19 P33261 2/20 0.54
CYP2C9 P11712 1/20 0.54
MAPT P10636 7/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.50
HTT P42858 1/20 0.50
TP53 P04637 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
POLB P06746 1/20 0.47
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341133 0.88 JAK2 (0.53) JAK2JAK3CYP1A2CYP2C19CYP2C9
SCHEMBL3344993 0.84 CYP1A2 (0.52) JAK2JAK3CYP1A2CYP2C19CYP2C9
SCHEMBL1327845 0.81 MAPT (0.45) CYP1A2CYP2C19CYP2C9MAPTALDH1A1
SCHEMBL3341192 0.81 ALDH1A1 (0.54) CYP1A2CYP2C19CYP2C9MAPTALDH1A1
SCHEMBL3344136 0.80 BAZ2B (0.46) JAK2JAK3CYP1A2MAPTALDH1A1
SCHEMBL3341743 0.78 CYP1A2 (0.47) JAK2JAK3CYP1A2CYP2C19CYP2C9
SCHEMBL31636902 0.77 LDHA (0.52) JAK2JAK3ALDH1A1HPGDSMN1; SMN2
SCHEMBL16879383 0.76 NPC1 (0.45) SMN1; SMN2NPC1RAB9APOLB
SCHEMBL12929431 0.75 ALDH1A1 (0.75) JAK2JAK3CYP1A2CYP2C19CYP2C9
SCHEMBL3652621 0.75 BAZ2B (0.51) CYP1A2MAPTALDH1A1HPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS PPARA, PPARD, PPARG JAK2 1106/4885JAK3 1878/4885CYP1A2 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.